Abstract | INTRODUCTION: METHOD: RESULTS: There were no significant changes in serum levels of MMP-3 (P > 0.05), VEGF (P > 0.05), and BALP (P > 0.05) in a large cohort of TNF-alpha blocker-naïve AS patients followed for 2 years. In contrast, adalimumab-treated spondyloarthritis (AS and non-radiographic axial spondyloarthritis) patients had a significant decrease of VEGF (P < 0.001) and MMP-3 (P = 0.022) after 36 to 52 weeks of therapy. Most interestingly, the level of BALP increased significantly after 36 to 52 weeks of therapy (P < 0.001). A decrease in MMP-3 serum levels correlated significantly to an increase of BALP (r = -0.398, P = 0.02). In the case of VEGF, there was a negative correlation without significance (r = -0.214, P > 0.05). CONCLUSIONS: Rising levels of BALP and the negative correlation between MMP-3 and BALP in spondyloarthritis patients with TNF-alpha blocker treatment indicate that new bone formation in AS occurs if inflammation is successfully treated and might be part of a healing process.
|
Authors | Heiner Appel, Louise Janssen, Joachim Listing, René Heydrich, Martin Rudwaleit, Joachim Sieper |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 10
Issue 5
Pg. R125
( 2008)
ISSN: 1478-6362 [Electronic] England |
PMID | 18945353
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Biomarkers
- Tumor Necrosis Factor-alpha
- Vascular Endothelial Growth Factor A
- Alkaline Phosphatase
- Matrix Metalloproteinase 3
- Adalimumab
|
Topics |
- Adalimumab
- Adult
- Alkaline Phosphatase
(blood, drug effects)
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Biomarkers
(blood)
- Bone and Bones
(drug effects, pathology)
- Cartilage
(drug effects, pathology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Male
- Matrix Metalloproteinase 3
(blood, drug effects)
- Spondylitis, Ankylosing
(blood, drug therapy, pathology)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, drug effects)
- Vascular Endothelial Growth Factor A
(blood, drug effects)
|